CASI Pharmaceuticals (CASI) announced that the first patient has been dosed in the Phase 1/2 trial to evaluate the safety and tolerability of CID-103 in adult patients with chronic Immune Thrombocytopenia in China. CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody recognizing a unique epitope that has demonstrated encouraging preclinical efficacy and safety profile compared to other anti-CD38 monoclonal antibodies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CASI:
- CASI Pharmaceuticals Faces Clinical Hold on CID-103 by FDA
- Casi Pharmaceuticals files $200M mixed securities shelf
- CASI Pharmaceuticals Faces Evomela® License Termination Dispute
- Berkshire reveals stake in Domino’s, Alibaba reports mixed Q2: Morning Buzz
- CASI Pharmaceuticals’ Mixed Third-Quarter Performance in 2024
Questions or Comments about the article? Write to editor@tipranks.com